Skip to content
Home

Poliomyelitis (polio): overview, course, prevention and history

Poliomyelitis is an infectious viral disease that can cause paralysis and death. Widespread vaccination has reduced cases by over 99% and remains central to eradication efforts.

Poliomyelitis, commonly called polio, is an infectious disease caused by poliovirus. The virus spreads mainly by the faecal–oral route and by direct person-to-person contact. Most infections are asymptomatic or cause only mild, flu-like symptoms; for a concise account of common presentations see symptoms and early signs. Only when the virus enters the bloodstream and spreads beyond the gut can it reach the central nervous system; the step of entering the bloodstream is therefore a key stage in the path toward more serious illness.

Image gallery

10 Images

Clinical features and complications

When poliovirus invades the nervous system it may infect the brain or spinal cord, damaging nerve cells that control muscles. This can produce weakness and acute flaccid paralysis. Targeted muscles include limb muscles, respiratory muscles and those used for swallowing; involvement of breathing muscles can lead to respiratory failure requiring mechanical support such as an iron lung historically and modern ventilatory care today. Some people recover strength over weeks to months; others are left with permanent weakness and disability and may need a mobility aid or a wheelchair. Difficulty with breathing or swallowing is described further at respiratory complications.

  • Typical non‑paralytic course: mild fever, sore throat, gastrointestinal upset, often unnoticed.
  • Paralytic polio: asymmetric flaccid paralysis that develops over hours to days and may be permanent.
  • Long‑term sequelae: lifelong weakness and, in some survivors, post‑polio syndrome — new muscle weakness and fatigue decades after acute infection.

Epidemiology and outcomes

Fatality and severity depend on age, the extent of nervous system involvement, and access to supportive care. Older sources have cited about 15 deaths per 10,000 adult infections as an estimate for overall adult mortality, but risk rises substantially among those with severe paralytic disease. Global incidence has fallen dramatically due to vaccination campaigns. International agencies such as the World Health Organization and partners track progress; comparisons of historical and later figures show dramatic reductions in illness and death over recent decades (trends and statistics).

Prevention: vaccines and public health measures

Polio is one of the few infectious diseases for which effective vaccines are the cornerstone of prevention. Two main vaccine types have been used widely: the inactivated polio vaccine (IPV) given by injection and the oral polio vaccine (OPV) given by mouth. Multiple doses are required to produce long-lasting immunity; booster doses may be recommended for travellers or people at increased risk. General information on vaccination is available at vaccination guidance and from official vaccine resources such as pages about polio vaccines. National public‑health agencies, including the Centers for Disease Control and Prevention, publish schedules and travel advice.

  1. Routine childhood immunization with IPV or OPV prevents most infections.
  2. High coverage and repeated mass campaigns are used to interrupt transmission.
  3. Surveillance for acute flaccid paralysis and environmental sampling detect remaining virus circulation.

History, eradication efforts and notable facts

Large epidemics in the first half of the 20th century led to major public concern and the development of vaccines by researchers such as Jonas Salk and Albert Sabin. The Global Polio Eradication Initiative launched in 1988 coordinated mass vaccination efforts and surveillance worldwide; at that time there were roughly 350,000 reported cases, and subsequent campaigns reduced cases by more than 99% in many regions. Progress has eliminated polio from most countries; however, complete eradication has been challenging due to political, logistical and biological obstacles, including rare vaccine-derived poliovirus outbreaks in under-immunized communities. For historical context and notable individuals affected by polio see the account of Franklin Delano Roosevelt, who lived with paralytic polio.

Today eradication remains a public-health priority. Continued high vaccine coverage, prompt outbreak response, and reliable surveillance are essential to prevent recurrence of transmission. For more technical resources and guidance from health authorities consult designated links on clinical features, vaccines and surveillance: symptoms, bloodstream spread, neuroinvasion, affected muscles, paralysis, mobility support, wheelchair needs, respiratory care, vaccination, vaccine types, WHO, global trends, CDC and historical notes.

Occurrence

Children between the ages of three and eight are predominantly affected; only occasionally do adults also fall ill. There is no causal treatment for this viral disease. Due to consistent vaccination, polio is now officially considered "eradicated" in Germany.

Poliomyelitis was first described clinically in the 18th century by the English physician Michael Underwood (1736-1820). The disease was described in more detail by the Black Forest orthopaedic surgeon Jakob Heine, who in 1840 published a book entitled Observations on paralytic conditions of the lower extremities and their treatment. What he described he called spinal polio in the second edition of 1860. The Swedish physician and researcher Karl Oskar Medin (1847-1927), who recognized the epidemic character of the disease, followed up on Heine's findings. Hence the further designation of polio as Heine-Medin disease.

According to current knowledge, poliomyelitis existed as an endemic disease until 1880. It was not until around 1880 that this infectious disease appeared in epidemic form, affecting thousands of people every year. Children in particular died from it or suffered permanent physical sequelae. From about 1910 onwards, regional epidemics occurred in Europe and the United States every five to six years. Among the best-known victims was the US President Franklin D. Roosevelt, who significantly promoted research for a vaccine during his presidency. The introduction of virus culture by J. F. Enders in 1952, thanks to which Jonas Salk developed an inactivated (dead) vaccine in 1954, is regarded as an advance in research into a vaccine. This, however, was insufficiently effective. The live attenuated vaccine developed by Albert Sabin made polio control possible from 1960. As a result, the number of polio cases fell from several 100,000 per year to about 1,000 per year.

In 2010, a severe outbreak occurred in Tajikistan, which also spread to Russia. On 5 May 2014, the World Health Organization (WHO) declared poliomyelitis outbreaks in Cameroon, Pakistan, and civil-war-torn Syria, and the spread from there to Equatorial Guinea, Afghanistan, and Iraq, an "extraordinary event" that required urgent coordinated action to prevent a global resurgence of the disease.

In early September 2015, WHO reported two cases of polio in children in southwestern Ukraine. There is a high risk of the disease spreading there. In that country, only 50% of children are vaccinated against polio. Because of better vaccination rates, there is little risk to neighboring Romania, Poland, Hungary, and Slovakia. In August 2019, Nigeria became the last African country to be officially declared poliomyelitis-free. Globally, new cases are reported in the endemic Afghanistan and Pakistan. There were 33 cases there in 2018, and these were joined by 72 new cases in Pakistan in 2019 (as of early October).

Pathogen

The causative agent of this disease is the poliovirus. It is an unsheathed virus with single-stranded RNA of positive polarity (ss(+)RNA) of approximately 30 nanometers in diameter, belonging to the genus Enterovirus of the family Picornaviridae. Three serotypes are known: Type 1 ("Brunhilde"), which is considered the most paralytic and tends to spread epidemically; it was named after a chimpanzee named Brunhilde who was infected at the time. In addition, there are type 2 ("Lansing") as well as type III ("Leon"), which have not been detected for years and have since been declared eradicated by the WHO. There is no cross-immunity between the three types of pathogen. This means that an infection with one of the three types does not protect against a further infection with one of the other two types. In addition to humans, a few great apes are also infected, and transmission in humans occurs through other humans.

Related articles

Author

AlegsaOnline.com Poliomyelitis (polio): overview, course, prevention and history

URL: https://en.alegsaonline.com/art/77737

Share

Sources